Format
Sort by

Send to

Choose Destination

Search results

Items: 12

1.

A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV Infection.

Margolick JB, Apuzzo L, Singer J, Wong H, Lee T, Gallant JE, El-Helou P, Loutfy MR, Rachlis A, Fraser C, Kasper K, Tremblay C, Tossonian H, Conway B.

PLoS One. 2015 Nov 24;10(11):e0143259. doi: 10.1371/journal.pone.0143259. eCollection 2015.

2.

A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study.

Cooper C, la Porte C, Tossonian H, Sampalis J, Ackad N, Conway B.

HIV Clin Trials. 2012 Jul-Aug;13(4):179-88. doi: 10.1310/hct1304-179.

PMID:
22849960
3.

Recent HIV-1 infection: to treat or not to treat, that is the question.

Tossonian H, Conway B.

J Infect Dis. 2012 Jan 1;205(1):10-2. doi: 10.1093/infdis/jir702. Epub 2011 Dec 15. No abstract available.

4.

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.

Yuan J, Guo S, Hall D, Cammett AM, Jayadev S, Distel M, Storfer S, Huang Z, Mootsikapun P, Ruxrungtham K, Podzamczer D, Haas DW; Nevirapine Toxicogenomics Study Team.

AIDS. 2011 Jun 19;25(10):1271-80. doi: 10.1097/QAD.0b013e32834779df.

5.

Comprehensive Approaches to the Diagnosis and Treatment of HIV Infection in the Community: Can "Seek and Treat" Really Deliver?

Conway B, Tossonian H.

Curr Infect Dis Rep. 2011 Feb;13(1):68-74. doi: 10.1007/s11908-010-0151-y.

PMID:
21308457
6.

Primary drug resistance in antiretroviral-naïve injection drug users.

Tossonian HK, Raffa JD, Grebely J, Viljoen M, Mead A, Khara M, McLean M, Krishnamurthy A, DeVlaming S, Conway B.

Int J Infect Dis. 2009 Sep;13(5):577-83. doi: 10.1016/j.ijid.2008.08.028. Epub 2008 Dec 25.

7.

Directly observed therapy with azithromycin for skin and soft tissue infections in injection drug users.

Tossonian HK, Conway B, Raffa JD, Viljoen M, Khara M, Mead A, Culbert H, Devlaming S.

Can J Infect Dis Med Microbiol. 2007 Jul;18(4):263-4. No abstract available.

8.

Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations.

Raffa JD, Tossonian HK, Grebely J, Petkau AJ, DeVlaming S, Conway B.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):397-9. No abstract available.

PMID:
18398974
9.

Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy program.

Tossonian HK, Raffa JD, Grebely J, Trotter B, Viljoen M, Mead A, Khara M, McLean M, Duncan F, Fraser C, DeVlaming S, Conway B.

J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):324-7.

PMID:
17468668
10.

The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program.

Raffa JD, Grebely J, Tossonian H, Wong T, Viljoen M, Khara M, Mead A, McLean M, Duncan F, Petkau AJ, DeVlaming S, Conway B.

Drug Alcohol Depend. 2007 Jul 10;89(2-3):306-9. Epub 2007 Mar 23.

PMID:
17383117
11.

Clinical implications of mutations at reverse transcriptase codon 135 on response to NNRTI-based therapy.

Tossonian HK, Raffa JD, Grebely J, Viljoen M, Mead A, Khara M, McLean M, Krishnamurthy A, Devlaming S, Conway B.

Open Virol J. 2007;1:8-13. doi: 10.2174/1874357900701010008. Epub 2007 Aug 20.

12.

A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective.

Conway B, Grebely J, Tossonian H, Lefebvre D, de Vlaming S.

Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S73-8. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk